Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advance...( Updated Clinical Phase 2 data prese...),Health

Updated Clinical Phase 2 data presented at American Society of Clinical

Oncology Annual Meeting

PRINCETON, N.J., June 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced updated long-term follow-up and overall survival (OS) results from a Phase 2 clinical study (MDX010-08) of 3 mg/kg of ipilimumab in combination with dacarbazine (DTIC) where 11.4%, or 4 of 35 patients, were still alive at or greater than 4 years of follow-up. This included 1 patient that experienced a complete response (4.7 years), 1 patient that experienced a partial response (4.2 years), 1 patient with stable disease (4.6 years) and 1 patient with RECIST defined progressive disease (4.4 years). The median OS for patients treated with ipilimumab in combination with DTIC was 15 months in this study. These results compare favorably with data in medical literature, in which median OS ranges from 6 to 9 months for patients with treated or previously untreated advanced melanoma treated with standard chemotherapy. These findings were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), being held in Chicago, IL May 30-June 3, 2008. (Abstract # 9022)

"The long-term survival data suggests that ipilimumab in combination with DTIC may have long-lasting effects," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "With a median survival of approximately 15 months in the patients treated with 3 mg/kg of ipilimumab in combination with DTIC in this Phase 2 study, we look forward with interest to the outcome of the ongoing Phase 3 study being performed by our collaborator Bristol-Myers Squibb Company, comparing 10 mg/kg of ipilimumab in combination with DTI
'/>"/>